Primary and secondary prophylactic administration of granulocyte-colony stimulating factor (G-CSF) for febrile neutropenia

Keita Uchino, Eishi Baba

Research output: Contribution to journalShort survey

Abstract

The Japanese guidelines for the proper use of granulocyte-colony stimulating factor (G-CSF) have been revised on the basis of the current international guidelines and latest evidence. The guidelines for primary and secondary prophylactic administration of G-CSF are clearly defined in the revised version. Primary prophylactic administration is recommended as per the incidence of febrile neutropenia (FN): it is highly recommended for patients with an FN rate > 20%, but selectively recommended for patients with an FN rate < 20%. Secondary prophylactic administration is recommended only for patients who should be maintained on a constant dose of G-CSF for curative purposes. The revised version aims to improve, not limit, the clinical use of G-CSF based on both patient- and evidence-oriented decisions in clinical practice.

Original languageEnglish
Pages (from-to)691-693
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Volume41
Issue number6
Publication statusPublished - Jan 1 2014

Fingerprint

Febrile Neutropenia
Granulocyte Colony-Stimulating Factor
Guidelines
Incidence

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Primary and secondary prophylactic administration of granulocyte-colony stimulating factor (G-CSF) for febrile neutropenia. / Uchino, Keita; Baba, Eishi.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 41, No. 6, 01.01.2014, p. 691-693.

Research output: Contribution to journalShort survey

@article{3ce1ccc3e94949fa9662284a02250443,
title = "Primary and secondary prophylactic administration of granulocyte-colony stimulating factor (G-CSF) for febrile neutropenia",
abstract = "The Japanese guidelines for the proper use of granulocyte-colony stimulating factor (G-CSF) have been revised on the basis of the current international guidelines and latest evidence. The guidelines for primary and secondary prophylactic administration of G-CSF are clearly defined in the revised version. Primary prophylactic administration is recommended as per the incidence of febrile neutropenia (FN): it is highly recommended for patients with an FN rate > 20{\%}, but selectively recommended for patients with an FN rate < 20{\%}. Secondary prophylactic administration is recommended only for patients who should be maintained on a constant dose of G-CSF for curative purposes. The revised version aims to improve, not limit, the clinical use of G-CSF based on both patient- and evidence-oriented decisions in clinical practice.",
author = "Keita Uchino and Eishi Baba",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "41",
pages = "691--693",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "6",

}

TY - JOUR

T1 - Primary and secondary prophylactic administration of granulocyte-colony stimulating factor (G-CSF) for febrile neutropenia

AU - Uchino, Keita

AU - Baba, Eishi

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The Japanese guidelines for the proper use of granulocyte-colony stimulating factor (G-CSF) have been revised on the basis of the current international guidelines and latest evidence. The guidelines for primary and secondary prophylactic administration of G-CSF are clearly defined in the revised version. Primary prophylactic administration is recommended as per the incidence of febrile neutropenia (FN): it is highly recommended for patients with an FN rate > 20%, but selectively recommended for patients with an FN rate < 20%. Secondary prophylactic administration is recommended only for patients who should be maintained on a constant dose of G-CSF for curative purposes. The revised version aims to improve, not limit, the clinical use of G-CSF based on both patient- and evidence-oriented decisions in clinical practice.

AB - The Japanese guidelines for the proper use of granulocyte-colony stimulating factor (G-CSF) have been revised on the basis of the current international guidelines and latest evidence. The guidelines for primary and secondary prophylactic administration of G-CSF are clearly defined in the revised version. Primary prophylactic administration is recommended as per the incidence of febrile neutropenia (FN): it is highly recommended for patients with an FN rate > 20%, but selectively recommended for patients with an FN rate < 20%. Secondary prophylactic administration is recommended only for patients who should be maintained on a constant dose of G-CSF for curative purposes. The revised version aims to improve, not limit, the clinical use of G-CSF based on both patient- and evidence-oriented decisions in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84906248125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906248125&partnerID=8YFLogxK

M3 - Short survey

C2 - 25129081

AN - SCOPUS:84906248125

VL - 41

SP - 691

EP - 693

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 6

ER -